

February 20, 2026

Ministry of Health and Medical Education
Iranian Food and Drug Administration
Islamic Republic of Iran

Subject: Report on a counterfeit Cyramza in Iran

Dear Sir/Madam,

We, Eli Lilly Export S.A. ("Lilly"), are writing to bring to your attention a counterfeit of Cyramza (RAMUCIRUMAB) INJ Vial 500MG 50ML, (the "Product"), which was brought to our attention following an inquiry from a patient.

A patient in Iran has contacted us to request verification of the authenticity of Cyramza (Ramucirumab) INJ Vial 500MG 50ML, batch number D519346S. The patient raised concerns regarding the product's authenticity. The origin of the Product could not be readily confirmed.

Please note that Cyramza (RAMUCIRUMAB) INJ Vial 500MG 50ML is not registered in Iran.


Following receipt of this report, Lilly requested additional information from the patient regarding the purchase and origin of the Product, however no response was received. Based on photos provided by patient, an investigation was conducted by Lilly, which confirmed that the Product is counterfeit.

In light of the presented matter, we respectfully request your intervention to take necessary actions against the availability of counterfeit pharmaceutical Products in Iran and to protect patient safety. We would appreciate any further findings related to this matter.

We reaffirm our commitment to patient safety and compliance with all applicable laws and regulations. We are available to provide any further clarification you may require.

Thank you for your attention to this matter.

Sincerely,

Summiyya Irshad 
Product Quality Associate

Annex 1 – Pictures received of the suspected product

